Janus Henderson Group PLC Trims Stake in IDEXX Laboratories, Inc. $IDXX

Janus Henderson Group PLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,790 shares of the company’s stock after selling 1,749 shares during the period. Janus Henderson Group PLC’s holdings in IDEXX Laboratories were worth $6,062,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter valued at about $26,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. Wormser Freres Gestion boosted its stake in IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the period. Finally, WealthCollab LLC purchased a new position in IDEXX Laboratories during the second quarter worth about $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $756.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $590.00 on Friday. The stock has a market capitalization of $46.48 billion, a price-to-earnings ratio of 41.49, a price-to-earnings-growth ratio of 3.17 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.82. The business has a 50-day moving average of $559.26 and a 200 day moving average of $585.78. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.